The following list of KPIs serve as baseline measurement for our corporate responsibility activities.
These indicators are measured globally unless otherwise noted and cover all our business units with the exception of joint ventures.
|ACCESS TO HEALTH||2011||2012|
|Research & Development|
|Top 20 global burdens of illness addressed by our products and pipeline1||53%||55%|
|GCP/PV audits by regulatory agencies of Merck or clinical trial investigators that led to significant fines, penalties, warning letters or product seizures||0||0|
|Initiated (new) licenses for new technologies||52||61|
|Narrative of compounds provided to Product Development Partnerships2||Online||Online|
|Manufacturing & Supply|
|Product recalls in the United States||0||4|
|Countries we currently supply with our products||140||140|
|Local and regional manufacturing partnerships3||130||84|
|Products available via local and regional manufacturing partnerships||NA||34|
|New product and device registrations4,5||334||437|
|Local regulatory agency GCP/PV training requests fulfilled that will help strengthen agency capabilities with their GCP/PV compliance oversight role6||Online||Online|
|Products submitted that have achieved WHO prequalification (cumulative)||10||10|
|Products for which we have access pricing7||19||19|
|Countries where at least one product has intra-country pricing of public and private sectors8||49||49|
|Investment into patient- and provider-education programs||$93.9M||$91.1M|
|Healthcare workers trained through major programs and partnerships9||51,600||38,166|
|Investment in partnerships for activities to address underlying barriers to health, such as health system strengthening and capacity building10||$34.7M||$23.8M|
|People reached through our major programs & partnerships9,11||255M||269M|
|Greenhouse gas emissions
(million metric tons of CO2e)
|Emissions of volatile organic compounds
|Water usage (billion gallons)||9.1||9.1|
|Waste generated (metric tons)||186,500||179,000|
|Waste recycling rate||54%||52%|
|Diversity & Inclusion|
|Executive roles held by women13,14
|Women on the Board||17%||17%|
|Underrepresented ethnic groups on the Board||11%||25%|
|Underrepresented ethnic groups in the
|Response rate to Merck and MSD Voice Survey||63%||77%|
|Employees who completed health
|Overall turnover rate15||14%||11%|
|Lost-Time Injury Rate (LTIR)16||0.30||0.24|
|Recordable Injury Rate (RIR)16||0.74||0.59|
|Employees who took release time according to the global policy on employee volunteerism17||11%||15%|
|ETHICS & TRANSPARENCY||2011||2012|
|Employees trained on our Code of Conduct||90%||92%|
|Substantiated allegations to concerns/issues raised||65%||60%|
|Reported concerns regarding privacy practices, breaches of privacy, and losses of personal data and devices that were substantiated18||68%||23%|
|NA: Not available.
1 As defined by the WHO and excluding accidents, premature births and self-inflicted injuries.
2 For information on product development partnerships, visit the “Partnerships” tab here.
3 The number of partnerships decreased in 2012 following the evaluation of the manufacturing capabilities needed to support and sustain our Access goals.
4 Data includes new products and new indications.
5 For information on new registrations by region, click here.
6 For information on local regulatory agency GCP/PV training requests, click here.
7 Differential pricing intended to facilitate access for the at-need population.
8 Countries with an MSD trading equity.
9 “Major” is defined as an investment by Merck’s Office of Corporate Philanthropy and/or The Merck Foundation of more than $300,000 per year and/or an engagement with a national government.
10 Includes investments by Merck’s Office of Corporate Philanthropy and/or The Merck Foundation; also includes funding for nutrition and access to clean water.
11 Includes treatments approved for river blindness and lymphatic filariasis through the Merck MECTIZAN® Donation Program.
12 For more details on our environmental metrics, please download the Excel spreadsheet on our Downloads & Media page.
13 Beginning with 2012, data reported for women are global; previously, these data were limited to the U.S.
14 “Executive” is defined as the Chief Executive Officer and two structural levels below.
15 Overall turnover incorporate all types of turnover, including restructuring.
16 LTIR/RIR: Calculated per OSHA methodology.
17 Figures are based on data collected, reported and estimated worldwide.
18 Privacy concerns include all concerns escalated to the Merck Privacy Office about the company’s privacy practices. Substantiated concerns are those that are determined to be inconsistent with Merck privacy standards or that involve loss, theft or unauthorized access to personal data.
Last Updated August 1, 2013